Alexion Pharmaceuticals to Acquire Portola Pharmaceuticals

Paul, Weiss is advising Alexion Pharmaceuticals, Inc. in its acquisition of Portola Pharmaceuticals Inc., a commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders. Under the terms of the transaction, Alexion will acquire all of Portola’s outstanding shares at $18 per share in cash. The deal is expected to close in the third quarter of 2020, subject to customary closing conditions and regulatory approvals.

The Paul, Weiss team includes, among others, corporate partners Scott Barshay, John Kennedy and Raphael Russo; intellectual property partner Jonathan Ashtor; employee benefits partner Jean McLoughlin; litigation partner Jaren Janghorbani and counsel Rachel Fiorill; tax partner Robert Holo; real estate partner Peter Fisch; and antitrust counsel Yuni Sobel.